Chryseobacterium gleum in a man with prostatectomy in Senegal: a case report and review of the literature

O. Arouna, F. Deluca, M. Camara, B. Fall, B. Fall, A. Ba Diallo, J. D. Docquier, and S. Mboup

Abstract

Background: Here we report a rare case of a urinary tract infection due to Chryseobacterium gleum. This widely distributed Gram-negative bacillus is an uncommon human pathogen and is typically associated with health care settings.

Case presentation: We describe a case of urinary tract infection caused by Chryseobacterium gleum in a 68-year-old man of Wolof ethnicity (an ethnic group in Senegal, West Africa) who presented to our Department of Urology in a university teaching hospital (Hôpital Aristide Le Dantec) in Dakar, Senegal, 1 month after prostatectomy. The strain isolated from a urine sample was identified as Chryseobacterium gleum by mass spectrometry (Vitek matrix-assisted laser desorption/ionization, time-of-flight, bioMérieux) and confirmed by 16S ribosomal ribonucleic acid sequencing. The organism was resistant to a wide range of antibiotics, including carbapenem, due to a resident metallo-β-lactamase gene that shared 99% of amino-acid identity with Chryseobacterium gleum class B enzyme.

Conclusions: Infection by Chryseobacterium gleum is infrequent, and no such case has been previously reported in Africa. Despite its low virulence, Chryseobacterium gleum should be considered a potential opportunistic and emerging pathogen. Further studies on the epidemiology, pathogenicity, and resistance mechanisms of Chryseobacterium gleum are needed for better diagnosis and management.

Keywords: Chryseobacterium gleum case report, Urinary tract infection, Metallo-β-lactamase, CGB-1, resistance

Background

The genus Chryseobacterium (formerly Flavobacterium) [1], whose type species is Chryseobacterium gleum [2] and belongs to the family Flavobacteriaceae (phylum Bacteroidetes), represents a group of Gram-negative, non-fermenting, catalase-positive, and indole-positive aerobic bacilli. Chryseobacterium species are uncommon human pathogens, and most cases are nosocomial and are often associated with immunosuppression or indwelling devices. Chryseobacterium is typically found in soil, water, plants, and food products and can survive in hospital environments, chlorinated water, and wet surfaces, all of which serve as potential reservoirs of infection. A literature search revealed only a few published cases in countries including Hungary, India, Croatia, and Saudi Arabia [3–6]. In Senegal, two cases of meningitis due to Flavobacterium meningosepticum were diagnosed in the late 1970s [7] as well as one case of Chryseobacterium indologenes [8]. However, human C. gleum infection has not been previously reported in Africa.

Here, we report the first case of C. gleum infection occurring in Africa and provide a review of similar cases worldwide (Table 1).

Case presentation

A 68-year-old man of Wolof ethnicity (an ethnic group in Senegal, West Africa) presented to our Department of Urology with severe dehydration and general deterioration of condition 1 month after prostatectomy performed at a regional hospital. At hospital admittance, a clinical examination found a high blood pressure (180/90 mmHg) and a fever of 38.5 °C. Blood tests found leukocytosis with a level of 17,100/mL white blood cells (WBC), anemia with a level...
of 10 g/dL, and creatinine with a level of 513.3 μmol/L. Serum electrolytes showed hyponatremia with a level of 111 mEq/L, hypokalemia with a level of 3.3 mEq/L, and hypochloremia with a level of 77 mEq/L. At presentation, he had an indwelling urinary catheter draining urine incorrectly that required a urine bacteriology examination.

Treatment consisted of fluid and electrolyte replacement, daily dressing of the wound, and empiric antibiotic therapy with amikacin. This drug was chosen because of the severity of the infection and because our patient had previously received treatment with fluoroquinolones. Seven days after hospitalization, the outcome was favorable with a clean surgical wound and normalization of serum potassium and chloride levels. However, hyponatremia persisted at 119 mEq/L, and his serum creatinine level was 111 mEq/L, hypokalemia with a level of 3.3 mEq/L, and creatinine with a level of 513.3 μmol/L. Removal of the urinary catheter was performed on day 7 of hospitalization, and he returned home the same day.

The cloudy urine collected for bacteriology examination at hospitalization was inoculated on a cysteine lactose electrolyte deficient (CLED) agar plate according to the usual techniques for medical bacteriology. Direct examination showed the presence of a rich bacterial flora, many white cells, and Gram-negative bacilli by Gram staining. The CLED agar grew yellow-colored 1 to 2 mm circular colonies, and Gram-negative bacilli by Gram staining. The examination showed a rich bacterial flora, many white cells, and Gram-negative bacilli by Gram staining. The CLED agar grew yellow-colored 1 to 2 mm circular colonies, and Gram-negative bacilli by Gram staining.

Identification of the strain using Appareil et Procédés d'Identification 20 NE (V7.0) was performed using genomic deoxyribonucleic acid (DNA) sequencing. In this case, Chryseobacterium gleum was confirmed as the causative agent for our patient’s urinary tract infection as evidenced from the culture reports. Confluent growth of the organism in pure form from urine helped to rule out contamination.

Antimicrobial susceptibility testing using disc diffusion and E-tests (bioMérieux) for the minimum inhibitory concentration (MIC) using Pseudomonas aeruginosa ATCC 27853 and Escherichia coli ATCC 25922 for internal quality control was completed and interpreted per the Comité d'Antibiogramme de la Société Française de Microbiologie (CA-SFM) recommendations of 2015. The isolated strain was susceptible to piperacillin (MIC = 6 μg/mL), cefazidime (MIC = 0.75 μg/mL), cefepime (MIC = 0.125 μg/mL), ciprofloxacin (MIC = 0.25 μg/mL), imipenem (MIC = 2 μg/mL), and resistant to meropenem (MIC = 8 μg/mL), aztreonam (MIC ≥256 μg/mL), ticarcillin (MIC ≥256 μg/mL), ticarclin-clavulanic acid (MIC = 64 μg/mL), and cefotaxime (MIC >32 μg/mL; Table 3).

Due to the decreased susceptibility to carbapenem, a combined test with imipenem and ethylendiaminetetraacetic acid (EDTA) was positive, indicating the production of metallo-β-lactamase (MBL). To characterize the gene encoding MBL, polymerase chain reaction (PCR) was performed using genomic deoxyribonucleic acid (DNA) obtained by phenol–chloroform extraction, using the template primers CGB1_exp/fw (5'-GGGAATTCCATATGAAAATAAGCATTCCGTTTTTATTTTTATAAGTACAG) and CGB1_exp/rv (CGCGGATCTTATTTTATTTTAAAGATCACAG) as described previously by Bellais and colleagues [9]. DNA sequence analysis of the 726-base pairs (bp) amplified sequence is shown in Table 3.

Table 2 Identification of the strain using Appareil et Procédés d'Identification 20 NE (V7.0)

| % ID | T |
|-----|---|
| 24 H | 48 H | 24 H | 48 H |

%ID identification percentage (proximity relative to the different taxa in the database. It is determined whether the observed profile is closer to a particular taxon), T typically (the most typical profile is the one that has no tests against the identification compared with percentages in the database for that taxon).
fragments encoding a 242-amino acid preprotein showed 99% similarity with CGB-1 (Fig. 1).

Discussion

*C. gleum* is an unusual human pathogen that has been reported as the cause of early neonatal respiratory infection in three neonates [3]. The most common species causing human disease is *F. meningosepticum* followed by *C. indologenes* and *C. gleum* [10]. Typically thought of as an organism of low virulence, *C. gleum* may cause serious infections, particularly among immunocompromised patients. Colonization of this organism in patients can occur via contaminated medical devices involving fluids, such as intubation tubes, respirators, humidifiers, and incubators for newborns, as previously reported [11]. Almost, all publications available in the literature refer to long hospital stays with prolonged antibiotic treatment (>14 days), oncological disease, and most of the patients had immunosuppression or indwelling devices [8–11]. A recent case published in 2016 from Saudi Arabia, reported *C. gleum* pneumonia in a 6-month-old baby with nephrotic syndrome [6]. The patient, intubated, was previously on multiple courses of antibiotics including meropenem, ceftriaxone, and vancomycin. Virol *et al.* reported in 2014 a case of early neonatal respiratory infection due to *C. gleum* in Hungary [3]. In Croatia, Dijana *et al.* published in 2015 a case of *C. gleum* infection in a patient with malnutrition and hepatic lesion [5]. The patient with respiratory insufficiency had developed septic shock, which necessitated intubation and mechanical ventilation. Our patient underwent a prostatectomy in a regional hospital with indwelling catheter; he had a urinary tract infection due to *C. gleum*, similar to an Indian case reported by Ramya *et al.* in 2015 [4].

Little is known about the virulence factor(s) of the members of *Chryseobacterium*, although reports have indicated that biofilm and protease production are important mechanisms involved in the virulence of *Elizabethkingia meningoseptica* (formerly *Chryseobacterium meningosepticum*) and *C. indologenes* [11]. Biofilm production by *C. indologenes* in central venous catheter-related bloodstream infection was recently noted [12]. *E. meningosepticum* isolates

| Antibiotics | MIC (μg/mL) | IZD (mm) | Breakpoint* (μg/mL) | S (mm) | Categorization |
|-------------|-------------|----------|---------------------|--------|----------------|
| Ticarcillin | 256         | 0        | 16                  | 18     | Resistant      |
| Ticarcillin + AC | 8         | 16       | 18                  |        | Resistant      |
| Piperacillin | 6          | 26       | 16                  | 18     | Susceptible    |
| Cefazidime | 0.75        | 22       | 8                   | 16     | Susceptible    |
| Cefotaxime | >32         | 8        | -                   |        | Resistant      |
| Cefepine  | 0.125       | 37       | 8                   | 19     | Susceptible    |
| Aztreonam | 256         | 0        | 1                   | 50     | Resistant      |
| Imipenem  | 2           | 25       | 4                   | 20     | Susceptible    |
| Meropenem | 8           | 15       | 2                   | 18     | Resistant      |
| Ciprofloxacin | 0.25      | 30       | 0.5                 | 25     | Susceptible    |
| Co-trimoxazole | 0.094    | 28       | -                   |        | Susceptible    |

* MIC breakpoint not given, AC clavulanic acid, IZD inhibition zone diameter, MIC minimum inhibitory concentration, S Susceptibility

*Antimicrobial susceptibilities interpretation was done according to Comité d’Antibiogramme de la Société Française de Microbiologie 2015 recommendations using Pseudomonas species as reference.*

Table 3 In vitro antimicrobial susceptibilities of the strain, and interpretation according to Comité d’Antibiogramme de la Société Française de Microbiologie 2015 recommendations, using *Pseudomonas aeruginosa* ATCC 27853 and *Escherichia coli* ATCC 25922 as quality control

Fig. 1 Comparison of the amino acid sequence of β-lactamase CGB-1 with our strain. Broken lines indicate identical amino acid residues. The vertical arrow indicates the putative cleavage site for the leader peptide of CGB-1. Amino acids that may be involved in the binding of Zinc (Zn^{2+}) or/and water are indicated with a star. Shading corresponds to the single amino-acid mutation occurring in the gene of our strain.
demonstrated 100% biofilm-forming ability in Luria-Bertani (LB) media, and increasing biofilm production is associated with the mortality rates of infected patients [13]. Lo and Chang performed a focused study on 14 *C. gleum* isolates [14], and the strains were epidemiologically unrelated and originated primarily from urine and sputum. Their study demonstrated that 40% of *C. gleum* isolates could form a biofilm. The biofilm-forming potential of *C. gleum* appeared to be much lower than that of *E. meningoseptica*. Therefore, it was suggested that *C. gleum* might be less virulent than *E. meningoseptica* and *C. indologenes*. In fact, we previously reported a fatal case of urinary tract infection due to *C. indologenes* in a woman with acute leukemia [8]. This outcome is in contrast to the present case, where the patient survived despite an advanced state of malnutrition. Only 0.27% (50 of 18,569) of all processed non-fermenting Gram-negative bacilli (NFGNBs) and 0.03% (50 of 15,581) of isolates collected by the SENTRY Antimicrobial Surveillance Program during the 5-year period from 1997 to 2001 were members of the genera *Chryseobacterium* or *Elizabethkingia* (formerly *Chryseobacterium*), with the most frequent organisms being *E. meningoseptica*, *C. indologenes*, and *C. gleum* [15]. All 50 isolates were obtained from hospitalized patients, among which only two isolates (4%) were identified as *C. gleum*. The present case is the first reported case of a urinary tract infection in Africa by *C. gleum*, although *C. indologenes* was previously reported in Burkina Faso in 2007 [16], in Senegal in 2014 [8], and in Tunisia in 2015 [17]. However, in Senegal, two cases of meningitis due to *E. meningoseptica* were diagnosed in the late 1970s [7].

There are few data available on antimicrobial susceptibility and no standardized breakpoints for *Chryseobacterium* species in CA-SFM guidelines due to the small number of clinical isolates. Thus, selecting an antimicrobial agent for the treatment of *Chryseobacterium* species infections remains difficult, especially because of chromosomal resistance to many antibiotics used for Gram-negative bacteria. According to the SENTRY Antimicrobial Surveillance Program, the antimicrobials most active against *Chryseobacterium* species are quinolones and sulfamethoxazole-trimethoprim (>95% susceptibility) followed by piperacillin-tazobactam (90% susceptibility). Ciprofloxacin, cefepime, ceftazidime, piperacillin, and rifampicin showed reasonable activity (85% susceptibility), whereas aminoglycosides, other β-lactams, chloramphenicol, linezolid, and glycopeptides are not appropriate for treating infections caused by this organism [15]. This conclusion is in concordance with the drug susceptibility pattern of the strain isolated in Senegal. In fact, most *C. gleum* infections have been preferentially treated by newer generations of quinolones than by the combination of piperacillin-tazobactam (Table 1). However, the strain isolated in Saudi Arabia was resistant to piperacillin-

| Antibiotics               | Our strain | *Chryseobacterium gleum* CIP 103039 |
|---------------------------|------------|------------------------------------|
| Ticarcillin               | ≥256       | 256                                |
| Ticarcillin + AC          | 64         | 256                                |
| Piperacillin              | 6          | 2                                  |
| Ceftazidime               | 0.75       | 4                                  |
| Cefotaxime                | >32        | 32                                 |
| Cefepime                  | 0.125      | 1                                  |
| Aztreonam                 | ≥256       | >512                               |
| Imipenem                  | 2          | 2                                  |
| Meropenem                 | 8          | 8                                  |

AC, clavulanic acid; MIC, minimum inhibitory concentration

| Antibiotics | MIC (μg/mL) |
|-------------|-------------|
| Cefepime    | ≥256        |
| Cefotaxime  | >32         |
| Piperacillin| 6           |
| Ticarcillin | ≥256        |

**Conclusions**

To the best of our knowledge, this is the first case of a *C. gleum* infection reported in Africa. Despite their low virulence, *Chryseobacterium* species should be considered a potential opportunistic pathogen that can cause infection in hospitalized patients. This report highlights the emergence of *Chryseobacterium* infections in Africa and emphasizes the importance of strengthening hospital hygiene measures as well as the necessity to survey environmental bacteria that could cause hospital-acquired infections.

**Acknowledgements**

We thank the practitioners of our Department of Urology for clinical data and the staff of the Laboratory of Bacteriology of the Aristide Le Dantec University Hospital for their technical assistance. We also thank the researchers at the Department of Medical Biotechnology, University of Siena (Italy), where work continues on this topic.

**Funding**

Not applicable.

**Availability of data and materials**

Data sharing was not applicable to this article because no datasets were generated or analyzed during the current study.
Authors’ contributions
OA, FD, MC, BF, BF, ABD, JDD, and SM conducted the case review and contributed to the writing of the case report. All authors read and approved the final report.

Competing interests
The authors declare that they have no competing interests.

Consent for publication
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Ethics approval and consent to participate
The approval of the national ethics committee was solicited and has been obtained.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Laboratoire de Bactériologie-Virologie, CHNU Aristide Le Dantec, Université Cheikh Anta Diop, BP 7325 Dakar, Senegal. 2Dipartimento di Biotecnologie Mediche, Università degli Studi di Siena, Policlinico “Le Scotte”, V lotto, II piano, Viale Bracci, 16, 53100 Siena (SI), Italy. 3Service d’Urologie, CHNU Aristide Le Dantec, BP 7325 Dakar, Senegal. 4Fédérations des laboratoires, Hôpital Principal de Dakar, 1, Avenue Nelson Mandela, Dakar, Senegal.

Received: 15 December 2016 Accepted: 15 March 2017

Published online: 24 April 2017

References
1. Vandamme P, Bernardet J, Segers P, Kersters K, Holmes B. New perspectives in the classification of the flavobacteria: Description of Chryseobacterium gen. nov. Bergeyella gen. nov., and Empedobacter nom. rev. Int J Syst Bacteriol. 1994;44:827–31.
2. Holmes B, Owen RJ, Steigengaertl AG, Brenner DJ. Flavobacterium gleum, a new species found in human clinical specimens. Int J Syst Bacteriol. 1984;34:21–5.
3. Virok DP, Abrok M, Szel B, Tajti Z, Mader K, Urban E, Talosi G. Chryseobacterium gleum – a novel bacterium species detected in neonatal respiratory tract infections. J Matern Fetal Neonatal Med. 2014;27(18):1926–9.
4. Ramya TG, Sabitha B, Pravin D, Geetha R. Chryseobacterium gleum urinary tract infection. Genes Rev. 2015;10 suppl 1:50.

5. Dijana VB, Ozrenka Z, Branka B, Vanda P. Chryseobacterium gleum infection in patient with extreme malnutrition and hepatic lesion – case report. Signa Vitae. 2015;10 suppl 1:50–2.
6. Baha A, Naseebin E, Khalidoon A, Reem A. Chryseobacterium gleum pneumonia in an infant with nephrotic syndrome. IDCases. 2016;5:34–6.
7. Samb A, Chiron JP, Denis F, Sow A, Diop Ml. Flavobacterium meningosepticum meningitis. Clinical and bacteriological study of 2 cases treated in Senegal. Bull Soc Med A. 1977;22(1):84–91.
8. Arouna O, Camara M, Fall S, Ngom-Cisse S, Fall B, Ba-Diallo A, Diop-Ndiaye H, Toure-Kane C, Mboup S, Gaye-Diallo A. Chryseobacterium indologenes in a woman with acute leukemia in Senegal: a case report. J Med Case Rep. 2014;8:138.
9. Bellais S, Naas T, Nordmann P. Genetic and Biochemical Characterization of CGB-1, an Ambler Class B Carbapenem-Hydrolyzing Beta-Lactamase from Chryseobacterium gleum. Antimicrob Agents Chemother. 2002;46:2791–6.
10. Mandell GL, Douglas, Bennett JE. Principles and Practice of Infectious Diseases, 8th ed. New York: Elsevier; 2010. p. 3022–3.
11. Hsueh PR, Ting LJ, Yang PC, Ho SW, Hsieh WC, Luh KT. Clinical and microbiological characteristics of Flavobacterium indologenes infections associated with indwelling devices. J Clin Microbiol. 1996;34:1908–13.
12. Kodama Y, Nishimura M, Nakashima K, Ito N, Fukano R, Okamura J. Central intravascular catheter-related bacteremia due to Chryseobacterium indologenes after cord blood transplantation. Rinsho Ketsueki. 2013;54:305–10.
13. Lin PY, Chen HL, Huang CT, Su LH, Chiu CH. Biofilm production, use of intravascular indwelling catheters and inappropriate antimicrobial therapy as predictors of mortality in Chryseobacterium meningosepticum bacteraemia. Int J Antimicrob Agents. 2010;36:343–40.
14. Lo HH, Chang SM. Identification, characterization, and biofilm formation of clinical Chryseobacterium gleum isolates. Diagn Microbiol Infect Dis. 2014; 79(3):298–302.
15. Kirby JT, Sader HS, Walsh TR, Jones RN. Antimicrobial susceptibility and epidemiology of worldwide collection of Chryseobacterium spp. Report from the SENTRY Antimicrobial surveillance Program (1997-2001). J Clin Microbiol. 2004;42:445–8.
16. Zeba B, De Luca F, Dubus A, Delmarcelle M, Simpore J, Nacoulma JO, Rossolini GM, Frere JM, Docquier JD. IND-6, a highly divergent IND-type metallo-beta-lactamase from Chryseobacterium indologenes strain 597 isolated in Burkina Faso. Antimicrob Agents Chemother. 2009;53:4520–6.
17. Ben Salah I, Fekih Hassen M, Ben Haj Khalifa A, Ben Sik Ali H, Tilouche N, Kheder M, Batrous S. Chryseobacterium indologenes in ventilator-associated pneumonia: First reported case in Tunisia. Rev Pneumol Clin. 2015;71(6):374–5.
18. Garg S, Appannanavar SB, Mohan B, Taneja N. Pyonephrosis due to Chryseobacterium gleum: A first case report. Indian J Med Microbiol. 2015; 33(2):311–3.

Submit your next manuscript to BioMed Central and we will help you at every step:
• We accept pre-submission inquiries
• Our selector tool helps you to find the most relevant journal
• We provide round the clock customer support
• Convenient online submission
• Thorough peer review
• Inclusion in PubMed and all major indexing services
• Maximum visibility for your research

Submit your manuscript at www.biomedcentral.com/submit